YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
94 hedge funds and large institutions have $140M invested in Y-mAbs Therapeutics in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
94
Holders Change
-4
Holders Change %
-4.08%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
11
Increased
37
Reduced
32
Closed
14
Calls
$17K
Puts
$16K
Net Calls
+$1K
Net Calls Change
-$15K
Top Buyers
| 1 |
CP
Caligan Partners
New York
|
+$6.99M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$4.63M |
| 3 |
BlackRock
New York
|
+$3.03M |
| 4 |
Morgan Stanley
New York
|
+$2.61M |
| 5 |
CCIA
Campbell & Co Investment Adviser
Baltimore,
Maryland
|
+$562K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$2.22M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.89M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.89M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.34M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$1.17M |
